3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Intraepithelial Lesions
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Pelvic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lymphoma, T-Cell
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
pembrolizumab
14
Specimen Handling
8
Docetaxel
8
olaparib
7
Nivolumab
7
Gemcitabine
7
Trastuzumab
6
Paclitaxel
6
rucaparib
5
Magnetic Resonance Spectroscopy
5
Early Intervention, Educational
5
Biopsy
5
Standard of Care
4
Cyclophosphamide
4
Carboplatin
4
tisotumab vedotin
3
talazoparib
3
pertuzumab
3
durvalumab
3
atezolizumab
3
Taxes
3
Surveys and Questionnaires
3
Sirolimus
3
Radiotherapy
3
Psychiatric Rehabilitation
3
Methods
3
Irinotecan
3
Immunoglobulin G
3
Fulvestrant
3
Educational Status
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Solutions
×
Gynecologic
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled